Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

Peter J Crack; Moses Zhang; Maria Cristina Morganti-Kossmann; Andrew Morris; Jonathan M Wojciak; Jonathan K Fleming; Ila Karve; David K Wright; Maithili Sashindranath; Yona Goldshmit; Alison Conquest; Maria Daglas; Leigh Andrea Johnston; Robert Lindsay Medcalf; Roger A Sabbadini; Alice Pebay

doi:10.1186/1742-2094-11-37

Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

Peter J Crack, Moses Zhang, Maria Cristina Morganti-Kossmann, Andrew Morris, Jonathan M Wojciak, Jonathan K Fleming, Ila Karve, David K Wright, Maithili Sashindranath, Yona Goldshmit, Alison Conquest, Maria Daglas, Leigh Andrea Johnston, Robert Lindsay Medcalf, Roger A Sabbadini, Alice Pebay

Research output: Contribution to journal › Article › Research › peer-review

61 Citations (Scopus)

Abstract

Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury. FINDINGS: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes. Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.

Original language	English
Pages (from-to)	1 - 11
Number of pages	11
Journal	Journal of Neuroinflammation
Volume	11
Issue number	(Art. No: 37)
DOIs	https://doi.org/10.1186/1742-2094-11-37
Publication status	Published - 2014

Access to Document

10.1186/1742-2094-11-37

Cite this

Crack, P. J., Zhang, M., Morganti-Kossmann, M. C., Morris, A., Wojciak, J. M., Fleming, J. K., Karve, I., Wright, D. K., Sashindranath, M., Goldshmit, Y., Conquest, A., Daglas, M., Johnston, L. A., Medcalf, R. L., Sabbadini, R. A., & Pebay, A. (2014). Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. Journal of Neuroinflammation, 11((Art. No: 37)), 1 - 11. https://doi.org/10.1186/1742-2094-11-37

@article{5328987622104d00bef6113b1fba0412,

title = "Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes",

abstract = "Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury. FINDINGS: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes. Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.",

author = "Crack, {Peter J} and Moses Zhang and Morganti-Kossmann, {Maria Cristina} and Andrew Morris and Wojciak, {Jonathan M} and Fleming, {Jonathan K} and Ila Karve and Wright, {David K} and Maithili Sashindranath and Yona Goldshmit and Alison Conquest and Maria Daglas and Johnston, {Leigh Andrea} and Medcalf, {Robert Lindsay} and Sabbadini, {Roger A} and Alice Pebay",

year = "2014",

doi = "10.1186/1742-2094-11-37",

language = "English",

volume = "11",

pages = "1 -- 11",

journal = "Journal of Neuroinflammation",

issn = "1742-2094",

publisher = "BioMed Central",

number = "(Art. No: 37)",

}

Crack, PJ, Zhang, M, Morganti-Kossmann, MC, Morris, A, Wojciak, JM, Fleming, JK, Karve, I, Wright, DK , Sashindranath, M , Goldshmit, Y, Conquest, A, Daglas, M, Johnston, LA, Medcalf, RL, Sabbadini, RA & Pebay, A 2014, 'Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes', Journal of Neuroinflammation, vol. 11, no. (Art. No: 37), pp. 1 - 11. https://doi.org/10.1186/1742-2094-11-37

TY - JOUR

T1 - Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

AU - Crack, Peter J

AU - Zhang, Moses

AU - Morganti-Kossmann, Maria Cristina

AU - Morris, Andrew

AU - Wojciak, Jonathan M

AU - Fleming, Jonathan K

AU - Karve, Ila

AU - Wright, David K

AU - Sashindranath, Maithili

AU - Goldshmit, Yona

AU - Conquest, Alison

AU - Daglas, Maria

AU - Johnston, Leigh Andrea

AU - Medcalf, Robert Lindsay

AU - Sabbadini, Roger A

AU - Pebay, Alice

PY - 2014

Y1 - 2014

N2 - Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury. FINDINGS: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes. Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.

AB - Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury. FINDINGS: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes. Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.

UR - http://www.jneuroinflammation.com/content/pdf/1742-2094-11-37.pdf

U2 - 10.1186/1742-2094-11-37

DO - 10.1186/1742-2094-11-37

M3 - Article

VL - 11

SP - 1

EP - 11

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - (Art. No: 37)

ER -

Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

Abstract

Access to Document

Other files and links

Cite this